Mirae Asset Global Investments
RXRX icon

Mirae Asset Global Investments’s Recursion Pharmaceuticals RXRX Stock Holding History

Mirae Asset Global Investments’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.1K Sell
23,466
-3,759
-14% -$12.5K ﹤0.01% 1268
2026
Q1 		$83.6K Buy
27,225
+2,239
+9% +$8.65K ﹤0.01% 1208
2025
Q4 		$102K Buy
24,986
+8,466
+51% +$41.9K ﹤0.01% 1252
2025
Q3 		$80.6K Buy
16,520
+1,081
+7% +$5.68K ﹤0.01% 1260
2025
Q2 		$78.1K Buy
15,439
+2,219
+17% +$10.9K ﹤0.01% 1180
2025
Q1 		$76.8K Buy
13,220
+499
+4% +$3.64K ﹤0.01% 1158
2024
Q4 		$94K Sell
12,721
-74,818
-85% -$503K ﹤0.01% 1159
2024
Q3 		$611K Buy
87,539
+80,664
+1,173% +$578K ﹤0.01% 926
2024
Q2 		$52.1K Sell
6,875
-90,669
-93% -$791K ﹤0.01% 1242
2024
Q1 		$738K Sell
97,544
-8,128
-8% -$90.5K ﹤0.01% 1699
2023
Q4 		$1.04M Sell
105,672
-682
-0.6% -$4.86K ﹤0.01% 1597
2023
Q3 		$814K Buy
106,354
+25,178
+31% +$251K ﹤0.01% 1632
2023
Q2 		$605K Sell
81,176
-3,683
-4% -$25.8K ﹤0.01% 1858
2023
Q1 		$566K Buy
84,859
+14,219
+20% +$113K ﹤0.01% 1863
2022
Q4 		$545K Buy
70,640
+476
+0.7% +$4.67K ﹤0.01% 1838
2022
Q3 		$747K Buy
70,164
+33,161
+90% +$336K ﹤0.01% 1649
2022
Q2 		$301K Buy
+37,003
New +$248K ﹤0.01% 1987

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mirae Asset Global Investments's RXRX Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Recursion Pharmaceuticals (RXRX) stake by 14% in Q2 2026, selling an estimated $12.5K and leaving 23,466 shares worth $86.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

Mirae Asset Global Investments first reported a position in RXRX in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.04M in Q4 2023. 155 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Mirae Asset Global Investments held 23,466 shares of Recursion Pharmaceuticals worth $86.1K as of Q2 2026.
  • Mirae Asset Global Investments sold 3,759 Recursion Pharmaceuticals shares in Q2 2026, an estimated $12.5K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1268 holding.
  • Mirae Asset Global Investments first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Mirae Asset Global Investments's Recursion Pharmaceuticals position peaked at $1.04M in Q4 2023.
  • 155 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.